Use of GP73 in the diagnosis of non-alcoholic steatohepatitis and the staging of hepatic fibrosis

Abstract

Objective To evaluate the utility of Golgi protein 73 (GP73) in the diagnosis of non-alcoholic steatohepatitis (NASH) and hepatic fibrosis (HF) staging. Methods Ninety-one patients with non-alcoholic fatty liver disease (NAFLD) were allocated to NAFL (n = 46) and NASH (n = 45) groups according to their NAFLD activity score (NAS), and there were 30 healthy controls. Serum GP73 was measured by ELISA, GP73 protein expression was evaluated using immunohistochemistry, and FibroScan was used to determine liver hardness. Results The serum GP73 concentrations of the NAFL and NASH groups were significantly higher than those of controls. GP73 expression in the liver of the patients gradually progressed from absent or low to moderate or high. Serum GP73 positively correlated with liver expression, and the serum and liver GP73 of the patients positively correlated with FibroScan value and HF stage. There was a strong positive correlation of the combination of alanine aminotransferase, gamma glutamyl transferase and GP73 with NASH. The combination of serum GP73 and FibroScan value was found to predict NASH (NAS > 4) and advanced HF (stage ≥2) in patients with NAFLD using receiver operating characteristic analysis. Conclusion Serum GP73 may be useful in the diagnosis of NASH and the staging of HF.

Biomarcadores séricos para la evaluación de la fibrosis hepática

“…Recientemente, en pacientes con cirrosis compensada, se ha observado una relación entre niveles elevados de GP73 y peores resultados clínicos, como la descompensación, el desarrollo de hepatocarcinoma, y mortalidad relacionada con patología hepática [ 93 , 94 ]. Su uso también ha sido validado en pacientes con MASLD [ 95 ], ALD y hepatitis vírica [ 64 , 88 , 96 ], lo que demuestra su utilidad para el diagnóstico de fibrosis y cirrosis avanzada, presentando un valor diagnóstico mayor que los índices FIB-4 y APRI [ 97 ].…”

Serum biomarkers for liver fibrosis assessment

“…Recently, it has been demonstrated that in patients with compensated cirrhosis higher levels of GP73 are related to worse outcomes such as decompensation, hepatocarcinoma development, and liver-related deaths [ 93 , 94 ]. Its use also has been validated in MASLD [ 95 ], ALD and viral hepatitis patients [ 64 , 88 , 96 ], proving to be a useful tool in the diagnosis of advanced fibrosis and cirrhosis, even better than FIB-4 or APRI [ 97 ].…”

GOLM1 depletion modifies cellular sphingolipid metabolism and adversely affects cell growth

“…In addition, Golm1 expression is also known to be induced in the liver of mice fed with high-fat and highcholesterol cholate diet (7). Recent study also showed a positive correlation between hepatic GOLM1 mRNA expression and nonalcoholic steatohepatitis (NASH) (9). GOLM1 enhances metastasis by acting as a cargo adaptor protein for epidermal growth factor receptor recycling and signaling (10).…”